News
Press Releases:
Houston, TX – June 15, 2010 – DNAtrix, Inc., a biotechnology company developing oncolytic viruses for cancer therapy, announced today that Dr. Frank Tufaro has been appointed CEO of the company. Frank will remain on the Board of Directors, and Dan Watkins will assume the role of Board Chair.
Dr. Tufaro was one of the founders of Neurovir, Inc., a Vancouver-based biotech company with a mission to develop herpes-simplex virus oncolytic vectors for treating cancer. Dr. Tufaro, a former University of British Columbia Microbiology professor with extensive experience in virology and cancer, was a co-founder of Neurovir, the first company in the world to test herpes simplex virus vectors for cancer. He ultimately served as CEO, during which time he negotiated and executed the successful merger of NeuroVir with MediGene AG, and built the drug development team. In 2005 he founded Allera Health Products, Inc. a natural products company developing nutraceutical products for immunity.
About DNAtrix, Inc.
DNAtriX, Inc. is a Phase I clinical stage company with proprietary oncolytic virus technology platform for the treatment of cancer. It first clinical candidate, delta24-RGD adenovirus, is designed to be effective against 90-95% of all cancers. The company has focused on malignant brain tumors as its first indication.
Houston, TX – September 1, 2009 – DNAtrix, Inc., a biotechnology company focused on the development of oncolytic viruses for the treatment of cancer, announced today that Dr. Frank Tufaro is joining the DNAtrix Board of Directors as Executive Chairman.
Dr. Tufaro was one of the founders of Neurovir, Inc., a Vancouver-based biotech company with a mission to develop herpes-simplex virus oncolytic vectors for treating cancer. Dr. Tufaro, a former University of British Columbia Microbiology professor with extensive experience in virology and cancer, initially served as Chief Scientific Officer of Neurovir, where he managed all aspects of drug development. He then served as CEO, during which time he negotiated and executed the successful merger of NeuroVir with MediGene AG, and built the drug development team.
About DNAtrix, Inc.
DNAtriX, Inc. is a Phase I clinical stage company with proprietary oncolytic virus technology platform for the treatment of cancer. It first clinical candidate, delta24-RGD adenovirus, is designed to be effective against 90-95% of all cancers. The company has focused initially on malignant brain tumors as its first indication.
Houston, TX May 22, 2009 – DNAtrix, Inc. announced today that its Phase I clinical trial testing Delta24-RGD for the treatment of malignant brain tumors has completed its first dosing cohort.
The Phase I trial is currently underway at the MD Anderson Cancer Center in Houston, Texas. Three patients have been treated with Delta24-RGD to date, with no drug-related serious adverse events to report. The study is now clear to escalate to the second dosing cohort. For more information on the trial please visit www.clinicaltrial.gov.
Patients diagnosed with Glioblastoma multiforme have a life expectancy of 12-14 months from diagnosis despite aggressive surgery, radiation and chemotherapy. The DNAtrix oncolytic virus technology represents a powerful new modality for cancer therapy that can be used in combination with existing treatments.
About DNAtrix, Inc.
DNAtriX, Inc. is a Phase I clinical stage company developing proprietary oncolytic virus technology for the treatment of cancer. The mechanism of action of its first candidate, delta24-RGD adenovirus, is designed to be effective against 90-95% of all cancers. The company has initially focused on malignant brain tumors, including glioblastoma multiforme (GBM) as its first indication.
Houston, TX December 3, 2008 – DNAtrix, Inc. announced today the start of a Phase I clinical trial of their lead oncolytic virus product, Delta24-RGD, for the treatment of recurrent malignant gliomas. The Phase I trial is currently underway at the University of Texas MD Anderson Cancer Center in Houston, Texas.
The purpose of the Phase I trial is to establish the safety of Delta24-RGD and to find the appropriate therapeutic dosage. Patients diagnosed with Glioblastoma multiforme have a life expectancy of 12-14 months from diagnosis despite aggressive surgery, radiation and chemotherapy. The DNAtrix oncolytic virus technology represents a powerful new modality for cancer therapy that can be used in combination with existing treatments.
For information pertaining to recruitment and qualifications for the trial please visit www.clinicaltrial.gov, study number NCT00805376.
About DNAtrix, Inc.
DNAtriX, Inc. is a Phase I clinical stage company developing proprietary oncolytic virus technology for the treatment of cancer. The mechanism of action of its first candidate, delta24-RGD adenovirus, is designed to be effective against 90-95% of all cancers. The company has initially focused on malignant brain tumors, including glioblastoma multiforme (GBM) as its first indication.
Houston, TX November 19, 2008 – DNAtrix, Inc., a biotechnology company focused on the development of a unique oncolytic virus platform, announced today that they have received a $1 million Pre-seed Commercialization award from the Texas Emerging Technology Fund.
“This award will allow us to hit significant milestones. We believe this is a win for the company and our current and future investors,” said Gray Hancock, director of operations for DNAtrix.
In 2005, the Texas Legislature created the Texas ETF, offering $200 million dollars to assist small to mid-size technology companies in launching quickly, expediting the commercialization of new life-changing inventions out of the lab and into the hands of consumers, and improving research at Texas universities.
About DNAtrix, Inc.
DNAtriX, Inc. is a Phase I clinical stage company developing proprietary oncolytic virus technology for the treatment of cancer.. The mechanism of action of its first candidate, delta24-RGD adenovirus, is designed to be effective against 90-95% of all cancers. The company has initially focused on malignant brain tumors, including glioblastoma multiforme (GBM) as its first indication.